Kyverna Therapeutics, Inc. (KYTX) Cash Flow Statement
Where KYTX’s cash came from and went, 2025
December 31, 2025 · U.S. dollars- Cash from operations
- −$153.7M
- Capital expenditures
- $5,000
- Free cash flow
- −$153.7M
- Returned to shareholders
- —
- Change in cash
- $27.5M cash at year-end $124.6M
Drawn to scale: where the cash came from and how it was used. Hover for values.
KYTX operating cash flow, capex and free cash flow
KYTX cash flow trends, 2021–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$22.2M2021 | −$153.7M2025 | — | |
| Capital expenditures | $1.3M2021 | $5,0002025 | −75.0%/yr | |
| Free cash flow | −$23.4M2021 | −$153.7M2025 | — | |
| Free cash flow margin | −414.5%2021 | −525.0%2022 | −110.5 pts | |
| Stock-based compensation | $7.2M2021 | $10.1M2025 | +8.6%/yr | |
| Capex / revenue | 22.8%2021 | 10.9%2022 | −11.9 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
KYTX cash flow by activity
KYTX net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
KYTX cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Operating activities | |||||
| Net income | −$161.3M | −$127.5M | −$60.4M | −$28.9M | −$26.4M |
| Depreciation & amortization | $1.8M | $2.1M | $1.7M | $1.1M | $586,000 |
| Stock-based compensation | $10.1M | $8.4M | $2.2M | $929,000 | $7.2M |
| Change in working capital | −$1.1M | $7.9M | $3.4M | −$10.3M | −$4.5M |
| Other non-cash items | −$3.2M | −$5.1M | $605,000 | $1.1M | $850,000 |
| Cash from operating activities | −$153.7M | −$114.2M | −$52.4M | −$36.1M | −$22.2M |
| Investing activities | |||||
| Capital expenditures | −$5,000 | −$2.2M | −$621,000 | −$768,000 | −$1.3M |
| Investments (net) | $41.1M | −$160.9M | −$8.8M | −$14.1M | −$1.3M |
| Acquisitions & other investing | −$1.1M | $2.2M | $621,000 | $768,000 | $1.3M |
| Cash from investing activities | $40.0M | −$160.9M | −$8.8M | −$14.1M | −$1.3M |
| Financing activities | |||||
| Net borrowing (repayment) | −$808,000 | −$956,000 | −$781,000 | −$249,000 | −$41,000 |
| Shares issued | $140.6M | $341.2M | $59.9M | $12.0M | $72.5M |
| Other financing | $1.4M | −$3.1M | −$1.0M | $175,000 | $30,000 |
| Cash from financing activities | $141.2M | $337.1M | $58.1M | $11.9M | $72.5M |
| Summary | |||||
| Net change in cash | $27.5M | $62.0M | −$3.1M | −$38.3M | $49.1M |
| Cash at end of period | $124.6M | $97.2M | $35.2M | $38.3M | $76.6M |
| Free cash flow | −$153.7M | −$116.5M | −$53.0M | −$36.9M | −$23.4M |
| Free cash flow margin | — | — | — | −525.0% | −414.5% |
| Capex / revenue | — | — | — | 10.9% | 22.8% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$38.3M | −$39.7M | −$37.8M | −$36.8M | −$42.1M | −$44.6M | −$37.5M | −$34.5M | −$28.8M | −$26.7M | −$20.7M | −$15.5M |
| Depreciation & amortization | $434,000 | $351,000 | $368,000 | $415,000 | $515,000 | $501,000 | $563,000 | $558,000 | $530,000 | $482,000 | $462,000 | $438,000 |
| Stock-based compensation | $3.5M | $3.2M | $2.7M | $2.7M | $2.5M | $2.2M | $1.4M | $3.4M | $1.3M | $2.3M | $784,000 | $521,000 |
| Change in working capital | $123,000 | −$5.4M | $1.7M | −$8.9M | $8.2M | −$2.2M | $34,000 | $5.3M | $4.4M | −$1.8M | $1.0M | $3.4M |
| Other non-cash items | −$6.1M | $3,000 | −$527,000 | −$795,000 | −$1.1M | −$758,000 | −$1.6M | −$2.2M | −$1.6M | $246,000 | −$151,000 | $4,000 |
| Cash from operating activities | −$40.3M | −$41.6M | −$33.5M | −$43.3M | −$31.9M | −$44.9M | −$37.1M | −$27.5M | −$24.2M | −$25.5M | −$18.6M | −$11.1M |
| Investing activities | ||||||||||||
| Capital expenditures | −$293,000 | $0 | −$5,000 | −$392,000 | −$204,000 | $0 | −$532,000 | −$102,000 | −$1.0M | −$543,000 | −$334,000 | −$256,000 |
| Investments (net) | $36.7M | −$50.2M | −$16.8M | $22.6M | $29.2M | $5.6M | $29.2M | $676,000 | −$67.9M | −$122.9M | $31.7M | −$54.1M |
| Acquisitions & other investing | −$255,000 | $0 | −$532,000 | $392,000 | $204,000 | $0 | $532,000 | $102,000 | $1.0M | $543,000 | $334,000 | $256,000 |
| Cash from investing activities | $36.1M | −$50.2M | −$17.3M | $22.6M | $29.2M | $5.6M | $29.2M | $676,000 | −$67.9M | −$122.9M | $31.7M | −$54.1M |
| Financing activities | ||||||||||||
| Net borrowing (repayment) | −$95,000 | −$86,000 | −$85,000 | −$120,000 | −$262,000 | −$341,000 | −$247,000 | −$242,000 | — | — | — | — |
| Shares issued | $0 | $0 | $140.6M | $0 | $0 | $0 | $0 | $0 | $0 | $341.2M | $0 | $34.8M |
| Other financing | $3.9M | −$15,000 | $220,000 | $1.6M | −$387,000 | −$73,000 | $32,000 | $90,000 | −$569,000 | −$3.1M | −$1.4M | −$51,000 |
| Cash from financing activities | $3.8M | −$101,000 | $140.7M | $1.5M | −$649,000 | −$414,000 | −$215,000 | −$152,000 | −$569,000 | $338.0M | −$1.4M | $34.8M |
| Summary | ||||||||||||
| Net change in cash | −$388,000 | −$91.9M | $89.9M | −$19.3M | −$3.4M | −$39.8M | −$8.0M | −$27.0M | −$92.7M | $189.6M | $11.7M | −$30.5M |
| Cash at end of period | $32.4M | $32.2M | $124.6M | $34.2M | $54.0M | $57.4M | $96.6M | $104.7M | $131.6M | $224.9M | $35.2M | $23.5M |
| Free cash flow | −$40.6M | −$41.6M | −$33.5M | −$43.7M | −$32.2M | −$44.9M | −$37.6M | −$27.6M | −$25.2M | −$26.1M | −$18.9M | −$11.4M |
| Free cash flow margin | — | — | — | — | — | — | −1,857.4% | — | — | — | — | — |
| Capex / revenue | — | — | — | — | — | — | 26.3% | — | — | — | — | — |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
KYTX cash generation
In fiscal 2025 (ended December 31, 2025), Kyverna Therapeutics generated -$153.7 million of cash from operations and spent $0.0 million on capital expenditures, leaving free cash flow of -$153.7 million. Cash and equivalents rose by $27.5 million over the year.
Related: KYTX income statement, KYTX balance sheet. See the KYTX stock overview for the latest quote and news.
KYTX cash flow FAQ
What is Kyverna Therapeutics's free cash flow?
Kyverna Therapeutics's free cash flow was -$153.7 million in fiscal 2025: -$153.7 million of operating cash flow minus $0.0 million of capital expenditures It was -$116.5 million a year earlier..
How much cash does Kyverna Therapeutics generate from operations?
Kyverna Therapeutics generated -$153.7 million of cash from operating activities in fiscal 2025.
How much does Kyverna Therapeutics spend on capital expenditures?
Kyverna Therapeutics spent $0.0 million on capital expenditures in fiscal 2025, compared with $2.2 million the year before.